GHRP-6
A first-generation synthetic hexapeptide ghrelin receptor agonist studied for growth hormone release and pronounced appetite-stimulating effects.
Molecular Structure
Amino Acid Sequence
Molecular Formula
Molecular Weight
Half-Life
CAS Number
What is GHRP-6?
GHRP-6 (Growth Hormone Releasing Hexapeptide-6) is a synthetic hexapeptide developed in the 1980s by Cyril Bowers and colleagues as part of foundational research that established the existence of a then-unrecognized GH-releasing pathway distinct from GHRH. The work with GHRP-6 and related compounds eventually led to the discovery of ghrelin, the endogenous ligand of the receptor these synthetic peptides activate, by Kojima and colleagues in 1999. Historically, GHRP-6 is therefore one of the foundational compounds in modern ghrelin and growth hormone secretagogue research.
GHRP-6 is notable in research for two reasons. First, it has the strongest appetite-stimulating effect of the major GHRPs, making it useful in research contexts where increased food intake is a desired outcome (cachexia, malnutrition models, anorexia research). Second, its long history of use has produced an extensive published literature spanning decades, providing the comparative foundation against which newer, more selective GHRPs such as ipamorelin and hexarelin are characterized.
Mechanism of action
GHRP-6’s mechanisms of action have been investigated across multiple pathways:
- Ghrelin receptor activation: The peptide activates the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs, stimulating growth hormone synthesis and release through Gq/phospholipase C and Gs/cAMP signaling.
- Pronounced appetite stimulation: Unlike the more selective ipamorelin, GHRP-6 produces marked appetite increases through hypothalamic arcuate nucleus ghrelin receptor activation, closely mimicking native ghrelin’s orexigenic effects.
- Cortisol and prolactin elevation: Research has documented meaningful increases in cortisol, prolactin, and ACTH alongside GH release, reflecting broader hypothalamic-pituitary axis effects than seen with selective GHRPs.
- Gastrointestinal motility effects: Ghrelin receptor activation in the gut produces effects on gastric emptying and intestinal motility, reflecting the broader ghrelin signaling profile.
- Synergy with GHRH analogs: As with other GHRPs, GHRP-6 produces synergistic GH release when co-administered with GHRH receptor agonists through complementary receptor pathway activation.
These pathways are characterized in both preclinical models and limited human research.
Research applications
GHRP-6 has been investigated across several research domains, with the most active areas including:
- Foundational growth hormone research: GHRP-6 was used extensively in research that established the existence of the ghrelin receptor pathway and ultimately led to the discovery of endogenous ghrelin. It remains useful for studies of ghrelin receptor pharmacology where strong receptor activation is desired.
- Cachexia and appetite research: The distinctive appetite-stimulating effect makes GHRP-6 of interest in research contexts examining cachexia (muscle wasting in chronic illness), anorexia, malnutrition, and feeding behavior. Animal models have examined effects on food intake and body weight in disease states.
- Cardiac research: Some studies have examined cardiac effects of GHRP-6 similar to those reported for hexarelin, though the cardiac research literature is more developed for hexarelin specifically.
- Combination protocol research: GHRP-6 has been studied alongside GHRH analogs for synergistic GH release, though its use in combinations has largely been replaced by ipamorelin or hexarelin in modern research due to selectivity considerations.
- Comparative GHRP research: The compound serves as a research reference and starting point for evaluating newer-generation GHRPs, with the extensive GHRP-6 literature providing the baseline against which more selective compounds are characterized.
This compound is intended for laboratory research use only. It has not been approved for human therapeutic use by any regulatory agency.
Storage & reconstitution
In its lyophilized form, GHRP-6 tolerates ambient temperatures during shipping but should be stored long-term at -20°C, protected from light. Properly stored lyophilized peptide remains stable for 24 months or longer.
Once reconstituted with bacteriostatic water for injection, GHRP-6 solutions should be stored refrigerated at 2-8°C and used within 28 days. Avoid repeated freeze-thaw cycles, which can degrade peptide structure and reduce activity.
Visual inspection should be performed before each use. The reconstituted solution should be clear and colorless. Reject any solution that appears cloudy, discolored, or contains visible particulate matter.
For step-by-step reconstitution calculations, see our reconstitution calculator.
For laboratory research use only. The compound described on this page is intended exclusively for in vitro research and laboratory experimentation by qualified researchers and is not for human or veterinary use. It is not a drug, food, dietary supplement, or cosmetic, and has not been approved by the FDA, Health Canada, EMA, or any other regulatory authority for the diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition. The information provided on this page is for educational and reference purposes only and does not constitute medical advice. By accessing this content you confirm that you are a qualified researcher purchasing for legitimate laboratory purposes.